ABOUT PALL + CYTIVA

Cytiva and the Life Sciences business of Pall have united under the Cytiva name!

With a mission to advance therapeutics from discovery to delivery, combining our organizations just makes sense. Together, we bring broad and deep expertise along with an expansive portfolio of products and services to better support every customer, big and small. We are now even more prepared to help you deliver life-changing therapies to the patients who need them.

WEBINARS/EVENTS

  • Here, we discuss the relationship between the CCS and PUPSIT, highlight the role of sterilizing grade filtration in the control strategy, and talk about how this can change throughout the product life cycle.

  • Learn how to choose the best filtration device for your specific application and understand pore size, membrane material, well volumes and tip types.

  • Learn how we helped viral vector CDMO Exothera simplify and streamline their manufacturing process by adding a large-scale suspension-based manufacturing platform, from upstream through downstream processing of viral vectors of up to 2000 L..

  • Watch this webinar to hear about a collaboration that helped optimize their new filling line with single-use needles and reduced downtime.

  • In this webinar we compare gamma and X-ray irradiation and explain what testing has been completed and key milestones for readiness for industry.

  • Learn how you can develop reproducible and scalable processes for viral vector manufacturing in order to meet clinical and commercial market demand in very short timelines.

  • Explore collaboration between biomanufacturers and suppliers, and how partnerships can speed up single-use process implementation and reduce risk.

  • In this webinar you will learn how to choose the best filter plate for your specific applications and understand pore size, membrane material, well volumes and tip types.

  • Scaling gene therapy, mAb, or vaccine therapeutic drug products from bench to manufacturing involves a balancing act between project management, risk mitigation, and process parameter selection. In this webinar we explore the ways to apply best practices through implementation of the Biotech Integrated Solutions service architecture for large-scale manufacturing projects, ultimately accelerating speed to market.

  • Join our panel webinar and meet the authors of the recently published gene therapy Ebook: ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ downstream article.  Hear directly from the authors on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

  • Gene therapies provide innovative options for treating patients, particularly where other traditional therapeutics have been ineffective. The industry continues to grow and mature from research to approved therapeutics. In this panel webinar series, hear directly from the authors of the eBook  "Insights on Successful Gene Therapy Manufacturing and Commercialization" on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

  • Formulation and filling is a critical part of any drug manufacturing process and demands the highest levels of quality and reliability. Pall has a range of technologies and services that enables end users to carry out their operations with increased reliability and flexibility – while ensuring the product quality is designed into the manufacturing process. Using technology from the Allegro™ single-use portfolio, Pall sterilizing grade filters and Pall’s automated solutions ensure that manual interventions are minimized and increased sterility assurance is achieved.

  • Vaccine manufacturing is responding to challenges for increasing safety assurance and responsiveness in order to reduce the impact of pandemic such as SARS-CoV-2. Therefore, in-depth knowledge of microorganism pathogenicity leads to develop new type of vaccines such as recombinant and viral vaccines. In this presentation we will review the current main upstream vaccine production processes, considering the choice of expression system, the means by which the biological preparation is introduced into the production cell and how Pall’s flexible single-use bioreactors support rapid process development, scale-up and safeguard the quality of life-protecting vaccines and help assure compliance with cGMP.

  • Watch to learn how a SUT supplier and a biomanufacturer can successfully work together to create an effective training program for GMP-compliant, aseptic, single-use bioprocesses.

CONTACT INFORMATION

Cytiva

100 Results Way

Marlborough, MA 01752

UNITED STATES

Phone: (800) 526-3593